Viking Therapeutics, Inc.

Welcome to the Viking Therapeutics First Quarter 2026 Financial Results Conference Call. At this time, all participants are in the listen-only mode. Following management-prepared remarks, we will hold a Q&A session. To ask a question at this time, please press the star key followed by 1 on your touchtone phone. If anyone has difficulty hearing the conference, please press star 0 for operator assistance. As a reminder, this conference call is being recorded today, April 29, 2026. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Dyes. Thank you, and over to you.

Hello, and thank you all for participating in today's call.

Joining me today is Brian Land, Vikings President and CEO, and Greg Zanti, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, April 29, 2026, will contain forward-looking statements under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Vikings' expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date, and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings for the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Land for his initial comments.